カテーテル関連血流感染 (CRBSI) の世界市場の評価：薬剤クラス・治療法・感染源・流通チャネル・地域別の機会および予測 (2017～2031年)

世界のカテーテル関連血流感染 (CRBSI) の市場規模は、2024年から2031年の予測期間中にCAGR 5.35％を記録し、2023年の17億1,000万米ドルから、2031年には25億9,000万米ドルの規模に成長すると予測されています。

市場成長の推進因子は、侵襲的な医療処置の増加、高齢化人口の増加、世界のさまざまな地域における慢性疾患の有病率の増加です。

CRBSIの予防と治療のために、診断方法の強化や抗菌剤コーティングカテーテルなど、先進的な製品や技術の採用が増加しており、同市場に有利な成長機会をもたらしています。CRBSIという長期にわたる課題が最先端のソリューションの開発を促しています。不適切な滅菌処置や院内感染の有病率の増加は市場の需要を高める主な要因の一部です。研究機関や大手参入事業者が患者の安全性を促進する先進製品の開発に重点を置くようになっていることも市場の拡大をさらに後押ししています。

CRBSIに関する研究活動の増加

この疾患に関連するさまざまな合併症を理解し、CRBSIを追跡して最終的に症例数を減らすために、さまざまな研究活動や調査が行われています。2023年には、維持血液透析を受けている患者のCRBSIに関連する因子を明らかにするために、ガーナの3次病院で実施された横断研究が発表され、血液透析を受けている患者において、CRBSIの高い有病率が認められました。

参入事業者による新規治療法の開発に向けた取り組みの増加

CRBSIの治療および予防ソリューションの開発に向けて、さまざまな大手参入企業が尽力しています。2023年にはCorMedix, Inc.がDefenCathのFDA承認を取得しました。ヘパリンとタウロリジンを含有するこのカテーテルロック溶液は、中心静脈カテーテルによる慢性血液透析を受けている成人のCRBSIの治療と予防に役立ちます。水性ベースで無菌、透明、防腐剤フリーのDefenCathは、米国で承認された最初で唯一の抗菌カテーテルロック液です。

北米が大きな市場シェアを占める

同地域の市場拡大は、高齢者人口の増加、カテーテル挿入の必要性の増加、確立された医療インフラの存在、血液関連感染症治療のための急速な技術進歩に起因しています。Population Reference Bureauによると、65歳以上のアメリカ人は2022年から2050年にかけて47％増加すると推定されています。その数は5,800万人（2022年）から8,200万人（2050年）に増加する見通しであり、65歳以上の年齢層に占める割合は17％から23％に増加すると予想されています。

当レポートでは、世界のカテーテル関連血流感染 (CRBSI) の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のカテーテル関連血流感染 (CRBSI) 市場の展望

• 市場規模・予測
• 薬剤クラス別
  • セファゾリン
  • バンコマイシン
  • クロキサシリン
  • ダプトマイシン
  • その他
• 治療法別
  • 抗生物質ロック療法
  • 抗菌剤
• 感染源別
  • コアグラーゼ陰性ブドウ球菌
  • 酵母
  • シュードモナス属
  • 黄色ブドウ球菌
  • 腸球菌・連鎖球菌
  • 腸内グラム陰性桿菌
  • その他
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界のカテーテル関連血流感染 (CRBSI) 市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 薬剤クラス別
• 治療別
• 感染源別
• 流通チャネル別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Pfizer, Inc.
• Citius Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Ltd.
• Geistlich Pharma AG
• CorMedix, Inc.
• TauroPharm GmbH
• Fresenius SE & Co. KGaA
• Novartis AG
• Teva Pharmaceuticals
• Eli Lilly and Company

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 3. Global Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 4. Global Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 5. Global Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 6. Global Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7. Global Catheter-Related Bloodstream Infection Market Share (%), By Region, 2017-2031F
• Figure 8. North America Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 10. North America Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 11. North America Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 12. North America Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 13. North America Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14. North America Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
• Figure 15. United States Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 17. United States Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 18. United States Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 19. United States Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 20. United States Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. Canada Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 23. Canada Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 24. Canada Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 25. Canada Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 26. Canada Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Mexico Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 29. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 30. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 31. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 32. Mexico Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 35. Europe Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 36. Europe Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 37. Europe Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 38. Europe Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. Europe Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 42. Germany Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 43. Germany Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 44. Germany Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 45. Germany Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46. France Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 48. France Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 49. France Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 50. France Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 51. France Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Italy Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 54. Italy Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 55. Italy Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 56. Italy Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 57. Italy Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58. United Kingdom Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 60. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 61. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 62. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 63. United Kingdom Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Russia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 66. Russia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 67. Russia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 68. Russia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 69. Russia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70. Netherlands Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 72. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 73. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 74. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 75. Netherlands Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76. Spain Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 78. Spain Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 79. Spain Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 80. Spain Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 81. Spain Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82. Turkey Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 84. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 85. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 86. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 87. Turkey Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88. Poland Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 90. Poland Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 91. Poland Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 92. Poland Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 93. Poland Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. South America Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 96. South America Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 97. South America Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 98. South America Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 99. South America Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. South America Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 103. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 104. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 105. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 106. Brazil Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107. Argentina Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 109. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 110. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 111. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 112. Argentina Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Asia-Pacific Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 115. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 116. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 117. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 118. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119. Asia-Pacific Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
• Figure 120. India Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 122. India Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 123. India Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 124. India Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 125. India Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. China Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 128. China Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 129. China Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 130. China Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 131. China Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132. Japan Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 134. Japan Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 135. Japan Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 136. Japan Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 137. Japan Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138. Australia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 140. Australia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 141. Australia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 142. Australia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 143. Australia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144. Vietnam Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 146. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 147. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 148. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 149. Vietnam Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150. South Korea Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 152. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 153. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 154. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 155. South Korea Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156. Indonesia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 158. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 159. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 160. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 161. Indonesia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. Philippines Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 164. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 165. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 166. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 167. Philippines Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168. Middle East & Africa Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 170. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 171. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 172. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 173. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Middle East & Africa Catheter-Related Bloodstream Infection Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 177. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 178. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 179. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 180. Saudi Arabia Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181. UAE Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 183. UAE Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 184. UAE Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 185. UAE Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 186. UAE Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187. South Africa Catheter-Related Bloodstream Infection Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Catheter-Related Bloodstream Infection Market, By Volume, In Million Units, 2017-2031F
• Figure 189. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Drug Class, 2017-2031F
• Figure 190. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Treatment, 2017-2031F
• Figure 191. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Source of Infection, 2017-2031F
• Figure 192. South Africa Catheter-Related Bloodstream Infection Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Source of Infection Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global catheter-related bloodstream infection market is projected to witness a CAGR of 5.35% during the forecast period 2024-2031, growing from USD 1.71 billion in 2023 to USD 2.59 billion in 2031F. The market growth is driven by a rise in the number of invasive medical procedures, an increasing aging population, and a growing prevalence of chronic diseases in various regions across the globe.

The rising adoption of advanced products and technologies for the prevention and treatment of catheter-related bloodstream infections, including enhanced diagnostic methods and antimicrobial-coated catheters, is providing lucrative growth opportunities for the market. The long-posed challenges of catheter-related bloodstream infections are prompting the development of cutting-edge solutions. The increasing incidence related to improper aseptic procedures and the growing prevalence of hospital-acquired infections are some of the major factors bolstering the market demand. The increasing emphasis of research organizations and major market players on the development of advanced products that promote patient safety is further supporting the market expansion.

According to a ScienceDirect article, in the Elsevier Journal in December 2023, a team of researchers and The Flume Catheter Company, in the United Kingdom is working on the development and testing of a FLUME urinary catheter with relocated drainage holes and protected tip. The retaining balloon supports a static load of 700 grams and reduced trauma when forced evulsion was modeled. The catheter design aims to enhance patient safety and comfort while maximizing bladder drainage.

Increasing Research Activities on CRBSI

Various research activities and studies are being conducted to understand the different complications associated with the disease and track CRBSI to ultimately reduce the number of cases. In 2023, a cross-sectional study conducted at a tertiary hospital in Ghana to determine the factors associated with catheter-related bloodstream infections among patients who were on maintenance hemodialysis was published. The cross-sectional hospital-based study was conducted on patients who were receiving maintenance hemodialysis via central venous catheters. The risk factors that were predictive of catheter-related bloodstream infections were determined with the help of multivariate analysis using logistic regression. High prevalence of catheter-related bloodstream infections was noted among patients undergoing hemodialysis. The most common causative agent was Coagulase negative Staphylococci. As per the conclusion of the study, there is a high requirement for infection surveillance units in the renal unit for tracking catheter-related bloodstream infections and taking significant measures to reduce these infections. It was noted that the prevalence of catheter-related bloodstream infections among the participants was 34.2%. A contributing factor for the prevalence of CRBSI in the participants of the study may be the lack of utilization of antiseptic or antibiotic lock system.

Increasing Efforts Towards Development of Novel Treatments by Market Players

Various major market players are dedicated towards developing treatment and prevention solutions for catheter-related bloodstream infections. In 2023, CorMedix, Inc. received FDA approval for DefenCath. The heparin and taurolidine containing catheter lock solution aids in treating and preventing catheter-related bloodstream infections in adults undergoing chronic hemodialysis through a central venous catheter. The aqueous-based, sterile, clear, and preservative-free DefenCath is the first and only antimicrobial catheter lock solution approved in the United States. DefenCath will allow healthcare providers to reduce the risk of infections in patients suffering from underlying kidney failure. The approval of the product was based upon the findings from the Phase 3 LOCK-IT-100 clinical study. The multicentral, randomized, active control, double-blind trial analyzed the safety and efficacy of DefenCath in lowering the incidences of catheter-related bloodstream infections in patients undergoing chronic hemodialysis due to kidney failure.

North America Accounts for a Significant Market Share

The expansion of the market in the region can be attributed to the growth of the geriatric population, increased requirement for catheters insertion, presence of a well-established healthcare infrastructure and rapid technological advancements for treatment of blood related infections. According to the Population Reference Bureau, the number of Americans aging 65 years and older is estimated to witness a 47% increase from 2022 to 2050. The number is projected to increase from 58 million (in 2022) to 82 million (by 2050). The share of the 65-and-older age group is expected to increase from 17% to 23%.

Frequent catheterization is often required in the elderly if they are suffering from urinary retention, continence, cancer, and pressure ulcers, increasing the risk of catheter-related bloodstream infections. Long-term catheterization is preferred by various caretakers and healthcare professionals as it reduces their burden and allows them to focus on the other requirements of the patient. However, catheterization for long intervals of time can often lead to complications and cause catheter-related bloodstream infections.

Increasing Research Activities on Coagulase-Negative Staphylococcus Support Segment Growth

Undergoing research activities are expected to determine how to effectively manage catheter-related bloodstream infection caused by coagulase-negative staphylococcus. As per the clinical guidelines, the management of coagulase-negative staphylococcus causing catheter-related bloodstream infections requires antibiotic treatment for five to seven days along with catheter removal. According to an Antibiotics article published in May 2023, in National Library of Medicine, randomized clinical trials are being conducted with the aim to determine whether no administration of antibiotic therapy is effective and safe in low-risk episodes of catheter-related bloodstream infections caused by coagulase-negative staphylococcus. In the study, the patients suffering from CRBSI caused by coagulase-negative staphylococcus were randomized 1:1 after the withdrawal of catheter were opted to receive or not receive parenteral antibiotics that act against the isolated strain. The secondary endpoints of the study were septic embolism, persistent bacteremia, time until the disappearance of the fever, and time until microbiological cure. The primary endpoint was the occurrence of any complications related to the antibiotic therapy or bacteremia within the ninety days of the follow-up.

Online Pharmacies Expected to Witness Significant Growth Over the Forecast Period

Owing to the convenience offered by online pharmacies, including fast deliveries, this distribution channel has evolved from an alternative method for procuring medication and has gained immense popularity. Over the past few years more patients have recognized the convenient nature of shopping across these pharmacies, supplanting the reliance on retail pharmacies. According to a survey funded by Sanofi Consumer Healthcare, respondents indicated various advantages of online pharmacies including reduced costs for patients, convenience, and increased access for patients.

Online pharmacies eliminate the requirement of calling in a prescription, walking or driving to the pharmacy and waiting in line. The unparalleled levels of confidentiality and privacy offered by online pharmacies is further boosting the popularity of the distribution channel. The growth of the segment is facilitated by the rapid expansion of the internet services and ease of mail-order trade. Furthermore, the price transparency and accessibility offered by online pharmacies is encouraging consumers to adopt these channels for purchasing different medication.

Future Market Scenario (2024 - 2031F)

The catheter-related bloodstream infection (CRBSI) market is expected to witness significant growth in the coming years due to several factors including increasing emphasis on research and development activities and growing requirement for catheters in elderly patients.

The rising investments towards the healthcare and pharmaceutical industries is expected to offer lucrative growth opportunities to the market.

Various studies are being conducted to examine the risk of catheter-related bloodstream infections in patients with hemodialysis catheters. For instance, Zealand University Hospital is conducting an interventional study to examine the effects of ethanol (70%) as a lock solution. The study is estimated to conclude in April 2025.

University of Zurich is on the phase 4 of their interventional study aiming to understand the effect of vancomycin after catheter replacement. The randomized controlled trial will study the effect of a single dose of vancomycin on infection resolution after the replacement of catheter for suspected central line-associated bloodstream infection. The study is expected to conclude in December 2024.

Key Players Landscape and Outlook

Key participants in the catheter-related bloodstream infection market include Pfizer Inc., Citius Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., CorMedix, Inc., and Teva Pharmaceuticals. Increasing research and development activities and strategic partnerships between leading market players is expected to offer lucrative growth opportunities to the market.

In 2023, CorMedix, Inc. received FDA approval for DefenCath. According to FDA, the drug will reduce incidences of catheter-related bloodstream infections in adults receiving chronic hemodialysis via a central catheter due to kidney failure.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Catheter-Related Bloodstream Infection Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Drug Class
  • 4.2.1. Cefazoline
  • 4.2.2. Vancomycin
  • 4.2.3. Cloxacillin
  • 4.2.4. Daptomycin
  • 4.2.5. Others
• 4.3. By Treatment
  • 4.3.1. Antibiotic Lock Therapy
  • 4.3.2. Anti-microbial Agents
• 4.4. By Source of Infection
  • 4.4.1. Coagulase-Negative Staphylococcus
  • 4.4.2. Yeast
  • 4.4.3. Pseudomonas
  • 4.4.4. S. aureus
  • 4.4.5. Enterococci and Streptococci
  • 4.4.6. Enteric Gram-negative Bacilli
  • 4.4.7. Others
• 4.5. By Distribution Channel
  • 4.5.1. Hospital Pharmacies
  • 4.5.2. Retail Pharmacies
  • 4.5.3. Online Pharmacies
• 4.6. By Region
  • 4.6.1. North America
  • 4.6.2. South America
  • 4.6.3. Europe
  • 4.6.4. Asia-Pacific
  • 4.6.5. Middle East & Africa
• 4.7. By Company Market Share (%), 2023

5. Global Catheter-Related Bloodstream Infection Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Drug Class
    • 5.1.2.1. Cefazoline
    • 5.1.2.2. Vancomycin
    • 5.1.2.3. Cloxacillin
    • 5.1.2.4. Daptomycin
    • 5.1.2.5. Others
  • 5.1.3. By Treatment
    • 5.1.3.1. Antibiotic Lock Therapy
    • 5.1.3.2. Anti-microbial Agents
  • 5.1.4. By Source of Infection
    • 5.1.4.1. Coagulase-Negative Staphylococcus
    • 5.1.4.2. Yeast
    • 5.1.4.3. Pseudomonas
    • 5.1.4.4. S. aureus
    • 5.1.4.5. Enterococci and Streptococci
    • 5.1.4.6. Enteric Gram-negative Bacilli
    • 5.1.4.7. Others
  • 5.1.5. By Distribution Channel
    • 5.1.5.1. Hospital Pharmacies
    • 5.1.5.2. Retail Pharmacies
    • 5.1.5.3. Online Pharmacies
  • 5.1.6. United States*
    • 5.1.6.1. Market Size & Forecast
    • 5.1.6.1.1. By Value
    • 5.1.6.1.2. By Volume
    • 5.1.6.2. By Drug Class
    • 5.1.6.2.1. Cefazoline
    • 5.1.6.2.2. Vancomycin
    • 5.1.6.2.3. Cloxacillin
    • 5.1.6.2.4. Daptomycin
    • 5.1.6.2.5. Others
    • 5.1.6.3. By Treatment
    • 5.1.6.3.1. Antibiotic Lock Therapy
    • 5.1.6.3.2. Anti-microbial Agents
    • 5.1.6.4. By Source of Infection
    • 5.1.6.4.1. Coagulase-Negative Staphylococcus
    • 5.1.6.4.2. Yeast
    • 5.1.6.4.3. Pseudomonas
    • 5.1.6.4.4. S. aureus
    • 5.1.6.4.5. Enterococci and Streptococci
    • 5.1.6.4.6. Enteric Gram-negative Bacilli
    • 5.1.6.4.7. Others
    • 5.1.6.5. By Distribution Channel
    • 5.1.6.5.1. Hospital Pharmacies
    • 5.1.6.5.2. Retail Pharmacies
    • 5.1.6.5.3. Online Pharmacies
  • 5.1.7. Canada
  • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Drug Class
• 6.2. By Treatment
• 6.3. By Source of Infection
• 6.4. By Distribution Channel
• 6.5. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Pfizer, Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Citius Pharmaceuticals, Inc.
• 13.3. Glenmark Pharmaceuticals Ltd.
• 13.4. Geistlich Pharma AG
• 13.5. CorMedix, Inc.
• 13.6. TauroPharm GmbH
• 13.7. Fresenius SE & Co. KGaA
• 13.8. Novartis AG
• 13.9. Teva Pharmaceuticals
• 13.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer